Evidence map›Paper›PMID 36336956›Full record

ArticleHuman molecular genetics2023

A novel de novo FEM1C variant is linked to neurodevelopmental disorder with absent speech, pyramidal signs and limb ataxia.

Abhishek Anil Dubey, Magdalena Krygier, Natalia A Szulc, Karolina Rutkowska, Joanna Kosińska, Agnieszka Pollak, Małgorzata Rydzanicz, Tomasz Kmieć, Maria Mazurkiewicz-Bełdzińska, Wojciech Pokrzywa and 1 more

Open access · hybridFull text read
In one paragraph

Article in Human molecular genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Abhishek Anil DubeyLaboratory of Protein Metabolism, International Institute of Molecular and Cell Biology in Warsaw, 02-109 Warsaw, Poland.
Magdalena KrygierDepartment of Developmental Neurology, Medical University of Gdańsk, 80-952 Gdańsk, Poland.
Natalia A SzulcLaboratory of Protein Metabolism, International Institute of Molecular and Cell Biology in Warsaw, 02-109 Warsaw, Poland.
Karolina RutkowskaDepartment of Medical Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland.
Joanna KosińskaDepartment of Medical Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland.
Agnieszka PollakDepartment of Medical Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland.
Małgorzata RydzaniczDepartment of Medical Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland.
Tomasz KmiećDepartment of Neurology and Epileptology, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
Maria Mazurkiewicz-BełdzińskaDepartment of Developmental Neurology, Medical University of Gdańsk, 80-952 Gdańsk, Poland.
Wojciech PokrzywaLaboratory of Protein Metabolism, International Institute of Molecular and Cell Biology in Warsaw, 02-109 Warsaw, Poland.ORCID 0000-0002-5110-4462
Rafał PłoskiDepartment of Medical Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland.ORCID 0000-0001-6286-5526
Medical University of Warsaw · PLInternational Institute of Molecular and Cell Biology · PLGdańsk Medical University · PLChildren's Memorial Health Institute · PL

Funding

Enhancing and expanding the CGC Strain CollectionP40OD010440 · OD · UNIVERSITY OF MINNESOTA · PI Aric L Daul, Ann E. Rougvie · 2012 to 2026
$7.5M
NIH HHS P40 OD010440
6 · The paper itself

Abstract

The principal component of the protein homeostasis network is the ubiquitin-proteasome system. Ubiquitination is mediated by an enzymatic cascade involving, i.e. E3 ubiquitin ligases, many of which belong to the cullin-RING ligases family. Genetic defects in the ubiquitin-proteasome system components, including cullin-RING ligases, are known causes of neurodevelopmental disorders. Using exome sequencing to diagnose a pediatric patient with developmental delay, pyramidal signs and limb ataxia, we identified a de novo missense variant c.376G>C; p.(Asp126His) in the FEM1C gene encoding a cullin-RING ligase substrate receptor. This variant alters a conserved amino acid located within a highly constrained coding region and is predicted as pathogenic by most in silico tools. In addition, a de novo FEM1C mutation of the same residue p.(Asp126Val) was associated with an undiagnosed developmental disorder, and the relevant variant (FEM1CAsp126Ala) was found to be functionally compromised in vitro. Our computational analysis showed that FEM1CAsp126His hampers protein substrate binding. To further assess its pathogenicity, we used the nematode Caenorhabditis elegans. We found that the FEM-1Asp133His animals (expressing variant homologous to the FEM1C p.(Asp126Val)) had normal muscle architecture yet impaired mobility. Mutant worms were sensitive to the acetylcholinesterase inhibitor aldicarb but not levamisole (acetylcholine receptor agonist), showing that their disabled locomotion is caused by synaptic abnormalities and not muscle dysfunction. In conclusion, we provide the first evidence from an animal model suggesting that a mutation in the evolutionarily conserved FEM1C Asp126 position causes a neurodevelopmental disorder in humans.

Indexed as

Neurodevelopmental DisordersProteasome Endopeptidase ComplexAcetylcholinesteraseAnimalsAtaxiaCaenorhabditis elegansChildCullin ProteinsHumansSpeechUbiquitinUbiquitin-Protein Ligase ComplexesUbiquitin-Protein LigasesAcetylcholinesteraseCullin ProteinsFEM1C protein, humanProteasome Endopeptidase ComplexUbiquitinUbiquitin-Protein Ligase ComplexesUbiquitin-Protein Ligases

Identifiers

PMID36336956
PMCPMC10026218
OpenAlexW4308365539

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read19
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.